Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 2 3Phase 1/2 2Phase 3 1

Status

Unknown 2Suspended 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 2Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Prostatic Neoplasms 1

Interventions

Cisplatin 1519Carboplatin 1420Cyclophosphamide 1360Gemcitabine 1235Bevacizumab 1226Paclitaxel 1211Radiotherapy 1176Docetaxel 1080pembrolizumab 1028Oxaliplatin 936Capecitabine 901Fluorouracil 833Rituximab 729Doxorubicin 683Nivolumab 679Dexamethasone 666Etoposide 660Irinotecan 622Leucovorin 575Pemetrexed 510Drug Therapy 493Cetuximab 483Trastuzumab 469Cytarabine 466Magnetic Resonance Spectroscopy 458Filgrastim 446Prednisone 433Lenalidomide 409Specimen Handling 408Temozolomide 400

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × abivertinib × Clear all
NCT05361915 2024-03-18

Study to Assess Abivertinib in Combination With Abiraterone in Metastatic Castration Resistant Prostate Cancer

Sorrento Therapeutics, Inc.

Phase 2 Suspended
100 enrolled
Genitourinary

Prostatic Neoplasms

NCT03574402 2022-12-06

TRUMP

Guangdong Association of Clinical Trials

Phase 2 Unknown
400 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03300115 2019-02-19

Clinical Trial of the Efficacy and Safety of AC0010 in the Treatment of EGFR T790M Patients With Advanded NSCLC

Hangzhou ACEA Pharmaceutical Research Co., Ltd.

Phase 2 Unknown
222 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡